MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte- macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells

Blood

Volumn 92, Issue 3, 1998, Pages 959-967

  Urashima, Mitsuyoshi ^a   Teoh, Gerrard ^b   Chauhan, Dharminder ^b   Ogata, Atsushi ^b   Shirahama, Shuya ^b   Kaihara, Chiharu ^b   Matsuzaki, Masaharu ^b   Matsushima, Hiroshi ^b   Akiyama, Masaharu ^b   Yuza, Youki ^b   Maekawa, Kihei ^b   Anderson, Kenneth C ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOPROTEIN; PROTEIN P53;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; DNA SEQUENCE; GENE OVEREXPRESSION; GROWTH DISORDER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032147060     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.3.959     Document Type: Article

References (55)

1. CaHilly-Snyder L, Yang-Feng T, Francke U, George DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13:235, 1987
2. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBOJ 10:1565, 1991
3. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80, 1992
4. Price BD, Park SJ: DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 54:896, 1994
5. Momand M, Zambetti BP, Olson DC, George D, Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237, 1992
6. Barak Y, Gottlieb E, Juven-Gershon T, Oren M: Regulation of mdm2 expression by p53: Alternative splicing promoters produce transcripts with nonidentical translation potential. Genes Dev 8:1739, 1994
7. Chen JD, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB: Interaction between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91:2684, 1994
8. Barak Y, Juven T, Haffner R, Oren M: Mdm2 expression is induced by wild type p53 activity. EMBOJ 12:461, 1993
9. Haines DS. Landefs JE. Engle U, George DL: Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 14:1171, 1994
10. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206, 1995
11. Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203, 1995
12. Ziao ZX, Chen J, Levine AJ, Modjtahedi N, Zing J, Sellero WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694, 1995.
13. Martin K, Trouche D, Hagemeier C, Sorensen TS, LaThangue NB, Kouzarides T: Stimulation of E2F/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691, 1995
14. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RR, Herrmann F, Lubbert M: Mechanism of p53 alteration in acute leukemias. Leukemia 8:1673, 1994
15. Zhou M, Heager AM, Smith SD, Findley HW: Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85:1608, 1995
16. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP Schlossman RL, Anderson KC: MDM2 protein overexpression promotes proliferation and survival of plasma cell leukemia cells. Blood 90:1982, 1997
17. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794, 1994
18. Bueso-Ramos C, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617, 1993
19. Quensnel B, Preudhomme C, Osier D, Lepeley P, Collyn-dHooghe M, Facon T, Zandecki M, Fenauz P: Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 88:415, 1994
20. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158, 1994
21. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic, Re VD, Laurino L, Carbone A, Goiocchi M: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphoma. Blood 85:3239, 1995
22. Ridge SA, Dyer M, Greaves MF, Wiedemann LM: Lack of MDM2 amplification in human leukemia. Br J Haematol 86:407, 1994
23. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736, 1993
24. Waber P, Chen J, Nisen P: Infrequency of MDM2 gene amplification in pediatric solid tumours and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53:6028. 1993
25. Mosner J, Deppert W: p53 and mdm2 are expressed independently during cellular proliferation. Oncogene 9:3321, 1994.
26. Ungar S, Van de Maeren A, Tammilehto L, Linnainmaa K, Mattson K, Gerwin BI: High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 74; 1534, 1996
27. Kondo S, Morimura T, Barnett GR Kondo Y, Peterson JW, Kaakaji R, Takeuchi J, Toms SA, Liu J, Erbel B, Barna BP: The transforming activities of MDM2 in cultured neonatal rat astrocytes. Oncogene 13:1773, 1996
28. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunee J: Alternative spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Med 2:912, 1996
29. Griffin JD, Young D, Hermann F, Wiper D, Wagner K, Sabbath KD: Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67:1448, 1986
30. Hoang T, Nara N, Wong G, Clark S, Minden MD, McCulloch EA: Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood 68:313, 1986
31. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haematopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
32. Kinoshita T, Yokota T, Arai K-I, Miyajima A: Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GMCSF receptors. EMBOJ 14:266, 1992
33. Yonish-Rouach E, Renitzky D, Lotem J, Sacks L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
34. Collins MKL, Marvel J, Madle P, Opez-Rivas A: Interleukin-3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 176:1043, 1992
35. Rinaudo MS, Su K, Falk LA, Haldar S, Mufson RA: Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 86:80, 1995
36. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602, 1990
37. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Interleukin-6 inhibits Fasinduced apoptosis and SAP kinase activation in multiple myeloma cells. Blood 89:227, 1997
38. WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 90:279, 1997
39. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD: Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oneogene Raf-1. Exp Hematol 22:1111, 1994
40. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K Piao Y-F, Miyazono K, Urabe A, Takaku F: Establishment and characterization of a unique human cell line that proliferates dependent on GM-CSF, IL-3, orerythropoietin. J Cell Physiol 140:323, 1989
41. Chauhan D, Kharbanda SM, Ogata A, Urashirna M, Frank D, Malik N, Kufe DW, Anderson KC: Oncostatin M induces association of GRB2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med 182:1802, 1995
42. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales UB, Dedera DA, Schlossman RL, Anderson KC: Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells. Blood 87:1928, 1996
43. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 88:2219, 1996
44. INK4A tumor suppressor and immunoglobulin heavy chain genes: TGFβ/IL-7 inhibitory signaling mechanism. Leukemia 10:1576, 1996
45. INK4A in interleukin-6 mediated growth of multiple myeloma. Leukemia (in press)
46. INK4A expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res (in press)
47. INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Blood 90:4106, 1997
48. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
49. Gottlieb E, Haffner R, von Ruden T, Wagner EF, Oren M: Downregulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal. EMBO J 13:1368, 1994
50. Zhu YK Bradbury DA, Russell NH: Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemia cells. BrJ Cancer 69:468, 1994
51. Haupt Y, Maya R, Kaza S, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296, 1997
52. Kubbutat MHG, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299, 1997
53. Borellin F, Glazer RI: Induction of SP1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem 268:7923, 1993
54. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H: Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378, 1992
55. Chao J-R, Chen C-S, Wang T-F, Tseng L-H, Tsai J-J, Kuo M-L, Yen JJ-Y, Yen H-FY: Characterization of factor-independent variants derived from TF-1 hematopoietic progenitor cells: the role of the Raf/MAP kinase pathway in the anti-apoptotic effect of GM-CSF. Oncogene 14:721, 1997